SG11202000250PA - A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers - Google Patents

A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers

Info

Publication number
SG11202000250PA
SG11202000250PA SG11202000250PA SG11202000250PA SG11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA
Authority
SG
Singapore
Prior art keywords
msi
cancers
prevention
treatment
vaccine based
Prior art date
Application number
SG11202000250PA
Other languages
English (en)
Inventor
Alfredo Nicosia
Elisa Scarselli
Guido Leoni
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Publication of SG11202000250PA publication Critical patent/SG11202000250PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202000250PA 2017-07-12 2018-07-12 A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers SG11202000250PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (1)

Publication Number Publication Date
SG11202000250PA true SG11202000250PA (en) 2020-02-27

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000250PA SG11202000250PA (en) 2017-07-12 2018-07-12 A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers

Country Status (19)

Country Link
US (1) US11578109B2 (zh)
EP (1) EP3652606B1 (zh)
JP (1) JP7274223B2 (zh)
KR (1) KR20200029443A (zh)
CN (1) CN111328420B (zh)
AU (1) AU2018298849B2 (zh)
BR (1) BR112020000590A2 (zh)
CA (1) CA3069047A1 (zh)
DK (1) DK3652606T3 (zh)
ES (1) ES2940087T3 (zh)
FI (1) FI3652606T3 (zh)
HU (1) HUE061840T2 (zh)
IL (1) IL271966A (zh)
MX (1) MX2020000413A (zh)
NZ (1) NZ759940A (zh)
PL (1) PL3652606T3 (zh)
PT (1) PT3652606T (zh)
SG (1) SG11202000250PA (zh)
WO (1) WO2019012082A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210213116A1 (en) 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3827263A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
CA3106570A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
WO2020022899A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
CA3106574A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
TW202043256A (zh) * 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
WO2021228999A1 (en) * 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
AU2003232485A1 (en) * 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
EP2687540A1 (en) * 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
CN102449149B (zh) 2009-05-29 2014-04-23 莫佛塞斯公司 集合及其使用方法
KR20130043627A (ko) * 2010-04-09 2013-04-30 온코세라피 사이언스 가부시키가이샤 Cdca5 펩티드 및 이를 포함한 백신
AU2012230259B2 (en) * 2011-03-24 2017-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dominant negative HSP110 mutant and its use in prognosing and treating cancers
KR102015648B1 (ko) * 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Mphosph1 펩티드 및 이를 포함한 백신
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
BR112015013737B1 (pt) * 2012-12-13 2021-07-27 Ruprecht-Karls-Universitãt Heidelberg Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
US20140235456A1 (en) * 2012-12-17 2014-08-21 Virginia Tech Intellectual Properties, Inc. Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci
US11098367B2 (en) * 2014-01-27 2021-08-24 Yale University Methods of identifying patients responsive to immunotherapeutic strategies
TWI806815B (zh) * 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. PEPTIDE CONCATEMERIC EPITAOPE RNA

Also Published As

Publication number Publication date
IL271966A (en) 2020-02-27
PT3652606T (pt) 2023-03-16
US11578109B2 (en) 2023-02-14
ES2940087T3 (es) 2023-05-03
AU2018298849B2 (en) 2022-07-14
EP3652606A1 (en) 2020-05-20
JP2020532288A (ja) 2020-11-12
FI3652606T3 (fi) 2023-03-16
EP3652606B1 (en) 2023-01-11
CN111328420B (zh) 2023-07-25
DK3652606T3 (da) 2023-03-13
RU2019144505A3 (zh) 2021-08-12
MX2020000413A (es) 2020-09-28
WO2019012082A1 (en) 2019-01-17
KR20200029443A (ko) 2020-03-18
US20200222519A1 (en) 2020-07-16
PL3652606T3 (pl) 2023-04-24
RU2019144505A (ru) 2021-08-12
BR112020000590A2 (pt) 2020-07-14
WO2019012082A9 (en) 2019-05-02
CA3069047A1 (en) 2019-01-17
JP7274223B2 (ja) 2023-05-16
HUE061840T2 (hu) 2023-08-28
CN111328420A (zh) 2020-06-23
NZ759940A (en) 2023-07-28
AU2018298849A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
IL271966A (en) A universal vaccine based on common neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI)
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
GB2604416B (en) Tumor infiltating lymphocytes and methods of therapy
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL267795A (en) Combined treatment for cancer
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
HUE047542T2 (hu) A rák kombinált kezelése
IL260423B1 (en) Methods and preparations for increasing the potency of super antigen-mediated cancer immunotherapy
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
IL264589A (en) Combined treatment for pancreatic cancer
EP3411122A4 (en) CANCER VACCINES AND TREATMENT METHODS THEREWITH
IL266993A (en) Combined therapy for cancer treatment
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL267613A (en) Pancreatic cancer treatment
GB201812647D0 (en) Viral vectors and methods for the prevention or treatment of cancer
IL274748A (en) Improved cancer treatment
IL253642A0 (en) Combined treatment for cancer
IL262945A (en) Medicament for treatment and/or prophylactic treatment of breast cancer
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201704287D0 (en) Treatment of cancer
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer